Department of Medical Biosciences, Pathology, Umeå University, Umeå, Sweden.
Department of Oncology-Pathology, Karolinska University Hospital, Stockholm, Sweden.
Prostate. 2019 Apr;79(5):435-445. doi: 10.1002/pros.23749. Epub 2018 Dec 11.
Implantation of rat prostate cancer cells into the normal rat prostate results in tumor-stimulating adaptations in the tumor-bearing organ. Similar changes are seen in prostate cancer patients and they are related to outcome. One gene previously found to be upregulated in the non-malignant part of tumor-bearing prostate lobe in rats was the transcription factor CCAAT/enhancer-binding protein-β (C/EBPβ).
To explore this further, we examined C/EBPβ expression by quantitative RT-PCR, immunohistochemistry, and Western blot in normal rat prostate tissue surrounding slow-growing non-metastatic Dunning G, rapidly growing poorly metastatic (AT-1), and rapidly growing highly metastatic (MatLyLu) rat prostate tumors-and also by immunohistochemistry in a tissue microarray (TMA) from prostate cancer patients managed by watchful waiting.
In rats, C/EBPβ mRNA expression was upregulated in the surrounding tumor-bearing prostate lobe. In tumors and in the surrounding non-malignant prostate tissue, C/EBPβ was detected by immunohistochemistry in some epithelial cells and in infiltrating macrophages. The magnitude of glandular epithelial C/EBPβ expression in the tumor-bearing prostates was associated with tumor size, distance to the tumor, and metastatic capacity. In prostate cancer patients, high expression of C/EBPβ in glandular epithelial cells in the surrounding tumor-bearing tissue was associated with accumulation of M1 macrophages (iNOS+) and favorable outcome. High expression of C/EBPβ in tumor epithelial cells was associated with high Gleason score, high tumor cell proliferation, metastases, and poor outcome.
This study suggest that the expression of C/EBP-beta, a transcription factor mediating multiple biological effects, is differentially expressed both in the benign parts of the tumor-bearing prostate and in prostate tumors, and that alterations in this may be related to patient outcome.
将大鼠前列腺癌细胞植入正常大鼠前列腺会导致肿瘤刺激受肿瘤影响器官的适应。在前列腺癌患者中也观察到类似的变化,这些变化与预后相关。先前在大鼠带瘤前列腺叶的非恶性部分上调的一个基因是转录因子 CCAAT/增强子结合蛋白-β(C/EBPβ)。
为了进一步探索这一点,我们通过定量 RT-PCR、免疫组织化学和 Western blot 检查了正常大鼠前列腺组织中 C/EBPβ 的表达,这些组织围绕着生长缓慢的非转移性 Dunning G、生长迅速的低转移性(AT-1)和生长迅速的高转移性(MatLyLu)大鼠前列腺肿瘤,并且还通过免疫组织化学检查了接受观察等待治疗的前列腺癌患者的组织微阵列(TMA)。
在大鼠中,C/EBPβmRNA 在受肿瘤影响的前列腺叶中表达上调。在肿瘤和周围非恶性前列腺组织中,免疫组织化学检测到 C/EBPβ存在于一些上皮细胞和浸润的巨噬细胞中。受肿瘤影响的前列腺中腺体上皮细胞的 C/EBPβ表达程度与肿瘤大小、与肿瘤的距离和转移能力相关。在前列腺癌患者中,周围受肿瘤影响的组织中腺体上皮细胞中 C/EBPβ的高表达与 M1 巨噬细胞(iNOS+)的积累和良好的预后相关。肿瘤上皮细胞中 C/EBPβ的高表达与高 Gleason 评分、高肿瘤细胞增殖、转移和不良预后相关。
这项研究表明,转录因子 C/EBP-β 介导多种生物学效应的表达,在带瘤前列腺的良性部分和前列腺肿瘤中均有差异表达,并且这种变化可能与患者的预后相关。